<DOC>
	<DOCNO>NCT01046539</DOCNO>
	<brief_summary>This single site , double-blind , randomize , placebo-controlled , crossover study ass pharmacodynamics ( PD ) RDC-0313 coadministered buprenorphine 12 healthy , opioid-experienced , non-treatment-seeking subject .</brief_summary>
	<brief_title>Phase 1 Study Evaluate RDC-0313 Coadministered With Buprenorphine Opioid-Experienced Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>ALKS-33</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Subject must capable understand comply protocol sign informed consent Must 1855 year age Must body mass index 18.030.0 kg/m2 screen Female subject must agree use acceptable method contraception date consent two week last dose Subjects must willing use alcohol , tobacco , caffeine , xanthinecontaining product resident inpatient facility Subjects must experience opioid user meet follow criterion : 1 ) use opioids nontherapeutic purpose ( ie , psychoactive effect ) least 10 occasion past five year ; 2 ) use opioids least 2 time two year prior screen ; 3 ) physically dependent opioids , assess medical history naloxone challenge perform screen Must current piror significant hepatic , renal , endocrine , cardiac , nervous , psychiatric , gastrointestinal , pulmonary , hematologic , metabolic disorder . Must current past opioid , alcohol , durg dependence ( exclude nicotine caffeine ) show sign withdrawal follow naloxone ( Narcan ) challenge . Please contact site additional information exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>